Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Research Group GMP & T Cell Therapy

Prof. Dr. Stefan Eichmüller

T cell based immunotherapy approaches against cancer hold great promise as documented by the therapeutic success of checkpoint inhibitor application in numerous clinical trials. The “Research Group GMP & T Cell Therapy” explores T cell mediated tumor rejection, working out new concepts for clinical application. In particular, our team investigates the functional roles T cells and macrophages play in rejection of melanoma and breast cancer, with special focus on miRNAs involved in these processes. In this context, we are also investigating the effect of various irradiation regimens on T cell-mediated tumor rejection and the associated induction of so called abscopal effects.

Using murine and humanized animal models, the T Cell Therapy team investigates (a) tumor derived antigens and/or epitopes recognized by T cells, (b) analyzes the biological functions exerted by various T cell subsets, and (c) determines inhibitory and/or stimulatory factors with impact on immunological tumor defense. Aiming at the development of immunotherapy strategies for comprehensive tumor cell eradication, we are establishing novel combinatorial radio-immunotherapy concepts using different sources of radiation (photons, carbon heavy ions) in conjunction with antibody delivery against the immune checkpoint inhibitors PD-L1 and CTLA-4.

The translation of innovative tumor immunotherapy approaches into clinical routine constitutes a major goal of tumor immunology research programs located at Heidelberg. Our GMP unit has long-standing experience on the implementation of processing and preparation procedures for adoptive transfer of tumor-reactive T cells and holds official permission for the adoptive transfer of autologous T cells expanded ex vivo.

„GMP“ stands for „good manufacturing practice“, holding strict rules for the production of therapeutics according to the German Medicines Act.

Further information about our GMP activities is available on the German Website.


Prof. Dr. Stefan Eichmüller
GMP & T Cell Therapy (D210)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 6221 42 3380

Selected Publications

  • Hartmann L et al. (2022) Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. Cancer Lett. 500. Link to full text
  • Kehl N et al. (2022) IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. Journal for ImmunoTherapy of Cancer 10. Link to full text
  • Hartmann L et al. (2020) Photon versus carbon ion irradiation – immunomodulatory effects exerted on various murine tumor cell lines. Scientific Reports 10:21517. Link to full text
  • Eisel D et al. (2019) Cognate interaction with CD4+ T cells instructs tumor-associated macrophages to acquire M1-like phenotype. Front Immunol 10(219). Link to full text
to top
powered by webEdition CMS